Table 3.
Demographic and clinical characteristics of patients with low-grade dysplasia detected on visible gastric lesions or randomly and without low-grade dysplasia, before and after Helicobacter pylori eradication
| Parameters | With LGD (n = 28) | Without LGD (n = 57) | P value |
| Age, mean (SD), yr | 60.9 (8.2) | 53.7 (13.4) | 0.01a |
| Gender, n (%) | |||
| Female | 15 (53.6) | 38 (66.7) | 0.24 |
| BMI, mean (SD), kg/m2 | 25 (2.4) | 25 (2.3) | 1.0 |
| Alcohol users (12-24 g/dL/die), n (%) | 15 (53.6) | 12 (21.1) | 0.002b |
| Previous smokers, n (%) | 10 (35.7) | 2 (3.5) | < 0.0001c |
| Family history of gastric cancer, n (%) | 4 (14.3) | 0 | 0.001c |
| Family history of other cancer, n (%) | 6 (21.4) | 3 (5.3) | 0.001c |
| Autoimmune comorbidity | |||
| Autoimmune atrophic gastritis | 8 (28.6) | 4 (7) | 0.02c |
| Autoimmune thyroiditis | 3 (10.7) | 3 (5.3) | 0.39 |
| A. thyroiditis + vitiligo | 1 (3.6) | 0 | 0.33 |
| A. thyroiditis + Crohn’s disease | 1 (3.6) | 0 | 0.33 |
| A. thyroiditis + Sjögren syndrome | 0 | 1 (1.7) | 1.0 |
| Sjögren syndrome | 0 | 1 (1.7) | 1.0 |
| Type-1/2 diabetes mellitus | 1 (3.6) | 2 (3.5) | 1.0 |
| Skin psoriasis | 1 (3.6) | 0 | 0.33 |
| Rheumatoid arthritis | 0 | 1 (1.7) | 1.0 |
| APCA and/or AIF antibody positivity | 8 (28.6) | 4 (7) | 0.02c |
| H. pylori eradication scheme, n (%) | |||
| Quadruple1 | 17 (60.7) | 36 (63.2) | 0.82 |
| Modified triple2 | 9 (32.1) | 19 (33.3) | 0.91 |
| Triple3 | 1 (3.6) | 2 (3.5) | 1.0 |
| Sequential4 | 1 (3.6) | 0 | 0.33 |
| H. pylori eradication cycles, n (%) | |||
| One cycle | 22 (78.6) | 46 (86) | 0.82 |
| Two cycles | 6 (21.4) | 8 (14) | 0.82 |
| OLGA scale before5 | |||
| Stage 0 | 0 | 4 (7) | 0.3 |
| Stage 1-2 | 8 (28.6) | 48 (84.2) | < 0.0001b |
| Stage 3-4 | 20 (71.4) | 5 (8.8) | < 0.0001c |
| OLGA scale after6 | |||
| Stage 0 | 0 | 4 (7) | 0.3 |
| Stage 1-2 | 7 (25) | 44 (77.2) | < 0.0001b |
| Stage 3-4 | 21 (75) | 9 (15.8) | < 0.0001b |
| OLGIM scale before | |||
| Stage 0 | 0 | 40 (70.1) | < 0.0001c |
| Stage 1-2 | 12 (42.8) | 16 (28.1) | 0.17 |
| Stage 3-4 | 16 (57.1) | 1 (1.8) | < 0.0001c |
| OLGIM scale after | |||
| Stage 0 | 0 | 29 (50.9) | < 0.0001c |
| Stage 1-2 | 7 (25) | 24 (42.1) | 0.12 |
| Stage 3-4 | 21 (75) | 4 (7) | < 0.0001c |
| Gastritis at histology before, n (%) | |||
| Quiescent | 0 | 0 | 1.0 |
| Mild | 3 (10.7) | 16 (28.1) | 0.10 |
| Moderate-severe | 25 (89.3) | 41 (71.9) | 0.10 |
| Gastritis at histology after, n (%) | |||
| Quiescent | 26 (92.9) | 55 (96.5) | 0.59 |
| Mild | 2 (7.1) | 2 (3.5) | 0.50 |
| Moderate-severe | 0 | 0 | 1.0 |
| MALT hyperplasia before, n (%) | |||
| Absent | 10 (35.7) | 36 (63.2) | 0.02b |
| Mild | 10 (35.7) | 15 (26.3) | 0.37 |
| Moderate | 6 (21.4) | 5 (8.8) | 0.17 |
| Severe | 2 (7.2) | 1 (1.8) | 0.25 |
| MALT hyperplasia after, n (%) | |||
| Absent | 10 (35.7) | 36 (63.2) | 0.02b |
| Mild | 18 (64.3) | 21 (36.8) | 0.02b |
| Moderate | 0 | 0 | 1.0 |
| Severe | 0 | 0 | 1.0 |
Data are expressed as number of patients and percentage (in parenthesis).
Bismuth + Metronidazole + Tetracycline + Proton pump inhibitor.
Amoxicillin + Levofloxacin + Proton pump inhibitor.
Amoxicillin + Clarithromycin + Proton pump inhibitor.
Amoxicillin + Clarithromycin + Proton pump inhibitor Amoxicillin (5 d), then Clarithromycin + Metronidazole (5 d) + Proton pump inhibitor.
Before Helicobacter pylori eradication (by Sydney System).
After Helicobacter pylori eradication.
By t-test.
By χ2 test.
By Fisher’s exact test. BMI: Body mass index; SD: Standard deviation; APCA: Anti-parietal cell antibody; AIF: Anti-intrinsic factor; H. pylori: Helicobacter pylori; PPI: Proton pump inhibitor; OLGA: Operative Link on Gastritis Assessment; OLGIM: Operative Link on Gastric Intestinal Metaplasia; MALT: Mucosa-associated lymphoid tissue.